Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
3.485
-0.115 (-3.19%)
At close: Feb 11, 2026, 4:00 PM EST
3.480
-0.005 (-0.14%)
After-hours: Feb 11, 2026, 4:10 PM EST
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 163.89M in the quarter ending September 30, 2025, a decrease of -5.75%.
Revenue (ttm)
796.97M EUR
Revenue Growth
+78.52%
P/S Ratio
1.42
Revenue / Employee
166,451 EUR
Employees
4,788
Market Cap
1.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
| Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
| Dec 31, 2022 | 751.45M | 250.52M | 50.01% |
| Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
| Dec 31, 2019 | 446.44M | 71.03M | 18.92% |
| Dec 31, 2018 | 375.41M | 334.83M | 825.21% |
| Dec 31, 2006 | 40.58M | -1.26M | -3.02% |
| Dec 31, 2005 | 41.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 837.32M |
| ANI Pharmaceuticals | 826.88M |
| Collegium Pharmaceutical | 757.07M |
| Amphastar Pharmaceuticals | 723.31M |
| Pacira BioSciences | 716.79M |
| BioCryst Pharmaceuticals | 599.82M |
| Alvotech | 573.35M |
| Dynavax Technologies | 330.51M |
EVO News
- 4 weeks ago - Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access - Accesswire
- 5 weeks ago - Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Accesswire
- 2 months ago - Evotec: How Low A Company May Go While Still Being Attractive - Seeking Alpha
- 2 months ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 2 months ago - Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome - Accesswire
- 3 months ago - Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership - Accesswire
- 3 months ago - Evotec SE (EVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities - Accesswire